Home » Topics » BioWorld Science

BioWorld Science
RSS

Nanobiotix presents phase I data from phase I/II study of NBTXR-3 in HCC

Sep. 25, 2019

Positive topline results presented from phase II STAR study of tolperisone

Sep. 25, 2019

PhoenixMD receives FDA clearance to initiate phase I/Ib study of PMD-026

Sep. 25, 2019

Phase III study of StrataGraft regenerative tissue meets both primary endpoints

Sep. 25, 2019

Ovid announces positive initial data from ongoing ENDYMION extension trial of soticlestat

Sep. 25, 2019

European Commission approves Epidyolex for the treatment of LGS and Dravet syndrome

Sep. 25, 2019

Senolytics work as advertised

Sep. 25, 2019

GABA Therapeutics and ATAI Life Sciences to develop GRX-917 for the treatment of mood disorders

Sep. 25, 2019

Crysvita approved in Japan for FGF-23-related hypophosphatemic rickets and osteomalacia

Sep. 23, 2019

Syndax initiates phase I/II study of SNDX-5613 in relapsed or refractory leukemias

Sep. 23, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...